SNPX vs. SPRB, NERV, GOVX, HCWB, NRSN, SYBX, IPA, DWTX, BMRA, and EGRX
Should you be buying Synaptogenix stock or one of its competitors? The main competitors of Synaptogenix include Spruce Biosciences (SPRB), Minerva Neurosciences (NERV), GeoVax Labs (GOVX), HCW Biologics (HCWB), NeuroSense Therapeutics (NRSN), Synlogic (SYBX), ImmunoPrecise Antibodies (IPA), Dogwood Therapeutics (DWTX), Biomerica (BMRA), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical products" industry.
Synaptogenix vs.
Synaptogenix (NASDAQ:SNPX) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, community ranking, earnings, valuation, risk and media sentiment.
In the previous week, Spruce Biosciences had 1 more articles in the media than Synaptogenix. MarketBeat recorded 1 mentions for Spruce Biosciences and 0 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 0.00 equaled Spruce Biosciences'average media sentiment score.
10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 9.1% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Synaptogenix has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Synaptogenix's return on equity of -42.14% beat Spruce Biosciences' return on equity.
Synaptogenix has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500.
Synaptogenix has higher earnings, but lower revenue than Spruce Biosciences.
Spruce Biosciences received 37 more outperform votes than Synaptogenix when rated by MarketBeat users. However, 66.67% of users gave Synaptogenix an outperform vote while only 54.93% of users gave Spruce Biosciences an outperform vote.
Synaptogenix currently has a consensus target price of $14.00, indicating a potential upside of 373.13%. Spruce Biosciences has a consensus target price of $2.38, indicating a potential upside of 465.48%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Synaptogenix.
Summary
Synaptogenix and Spruce Biosciences tied by winning 7 of the 14 factors compared between the two stocks.
Get Synaptogenix News Delivered to You Automatically
Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Synaptogenix Competitors List
Related Companies and Tools
This page (NASDAQ:SNPX) was last updated on 2/22/2025 by MarketBeat.com Staff
